Metastatic Hormone Refractory Prostate Cancer Completed Phase 2 Trials for Abituzumab (DB12775)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01360840EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate CancerTreatment